# Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics

> **NCT04584008** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Peking University** · enrollment: 600 (actual)

## Conditions studied

- Biliary Tract Neoplasms
- Gastric Cancer
- Esophageal Squamous Cell Carcinoma
- Colorectal Cancer
- Gastrointestinal Stromal Tumors
- Pancreatic Cancer
- Neuroendocrine Tumors
- Unknown Primary Cancer
- Digestive Cancer

## Interventions

- **DRUG:** FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.
- **DRUG:** Other Therapy

## Key facts

- **NCT ID:** NCT04584008
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-23
- **Primary completion:** 2024-11
- **Final completion:** 2025-03
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04584008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04584008, "Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04584008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*